Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On March 31, 2023, Pyxis Oncology (Nasdaq: PYXS) announced the granting of restricted stock units totaling 54,010 shares and stock options for 67,513 shares to three new employees as part of its 2022 Inducement Plan. The vesting of these awards occurs over four years, with 25% vesting on the first anniversary, followed by monthly vesting for 36 months. The stock options feature a ten-year term with an exercise price of $4.01, reflecting the closing stock price on the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent to advance the company's mission against difficult-to-treat cancers.
Pyxis Oncology (Nasdaq: PYXS) reported full-year 2022 financial results and updates on its clinical trials. The company has initiated two Phase 1 trials for its candidates PYX-201 and PYX-106, with preliminary data expected by early 2024. As of year-end 2022, Pyxis maintained a strong balance sheet with $180.7 million in cash and no debt, funding operations into 1H 2025. Research and development expenses rose to $86.1 million, while general and administrative costs increased to $37.4 million, leading to a net loss of $120.7 million for 2022, equating to ($3.65) per share. The company also received FDA clearance for both candidates' INDs.
Pyxis Oncology (Nasdaq: PYXS) has achieved a major milestone by initiating dosing in a Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate targeting extradomain-B of fibronectin, which is overexpressed in various solid tumors. The trial aims to evaluate the safety and efficacy of PYX-201 with preliminary data expected in early 2024. The company emphasizes its innovative approach using three mechanisms of action to potentially improve treatment for patients with solid tumors. The trial is open to patients with relapsed or refractory cancers, paving the way for future therapeutic advancements.
Pyxis Oncology (Nasdaq: PYXS) is set to host investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will occur virtually. Key executives attending include Lara Sullivan, M.D. (President & CEO), Pamela Connealy (CFO), Jay Feingold, M.D., Ph.D. (CMO), and Jan Pinkas, Ph.D. (CSO). Institutional investors interested in participating can contact their SVB Securities representative or Jennifer Davis Ruff, VP of Investor Relations.
Pyxis Oncology focuses on developing next-generation therapeutics aimed at difficult-to-treat cancers, utilizing strategies such as antibody-drug conjugates and immuno-oncology programs.